PIL seeks action against Ranbaxy

The appeal filed in the Supreme Court also sought seizure of the properties of the directors of the company.

June 05, 2013 06:39 pm | Updated November 16, 2021 11:56 pm IST - New Delhi

A 40 mg tablet of Ranbaxy Laboratories Ltd.'s Storvas, a generic version of Lipitor, a cholesterol-lowering drug, is arranged for a photograph in Mumbai, India, on Thursday, April 3, 2007.  Ranbaxy Laboratories Ltd. will fight a challenge by Merck & Co., the third-largest U.S. drugmaker, to prevent it from marketing a generic copy of the antibiotic Primaxin I.M. on grounds the Indian company infringed a patent. Photographer: Scott Eells/Bloomberg News

A 40 mg tablet of Ranbaxy Laboratories Ltd.'s Storvas, a generic version of Lipitor, a cholesterol-lowering drug, is arranged for a photograph in Mumbai, India, on Thursday, April 3, 2007. Ranbaxy Laboratories Ltd. will fight a challenge by Merck & Co., the third-largest U.S. drugmaker, to prevent it from marketing a generic copy of the antibiotic Primaxin I.M. on grounds the Indian company infringed a patent. Photographer: Scott Eells/Bloomberg News

A Public Interest Litigation petition has been filed in the Supreme Court on Wednesday against the Directors of Ranbaxy Laboratories for allegedly manufacturing and selling adulterated drugs in India.

The PIL, which comes in the wake of the Indian pharma major being fined $500 million by the U.S. Food and Drug Administration (USFDA) for making and selling “adulterated” drugs, was mentioned for early listing by petitioner and advocate Manoharlal Sharma before a vacation Bench of Justices Ms. Gyan Sudha Misra and Madan B. Lokur. The Bench however told counsel that the matter could be mentioned after the technical formalities were completed by the Registry.

The petitioner sought prosecution of all directors of the company and a bar on any further sale of drugs manufactured by Ranbaxy and also seizure of the entire property of the directors of the firm. He claimed that despite Ranbaxy pleading guilty to supplying adulterated drugs in the U.S. and it being fined such a huge amount, the Centre had not taken any action to prohibit or ban the company’s drugs. He also sought action against the Central Drug Standards Control Organisation for permitting Ranbaxy to sell drugs in India, especially in the wake of the results of the USFDA investigation against the company.

The petitioner sought sealing of manufacturing facilities of the company at Paonta Sahib and Devas in Himachal Pradesh. He said the petition raised serious questions about whether our government could effectively safeguard drug supply. He alleged that supply of adulterated drug was a heinous crime and it amounted to committing murder and the various facts had clearly disclosed that Ranbaxy had been supplying adulterated drug in India and other countries. He wanted the licence of the company be cancelled coupled with imposition of heavy penalty in billions of dollars to compensate cost of lives taken by the Ranbaxy medicines.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.